Myricx Bio Appoints Jonathon Marks-Bluth as VP, Business Development
London, UK, 8 September 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of Jonathon Marks-Bluth, Ph.D., to its leadership team in the newly created position of VP, Business Development.